Govindaraj, Chindu <br/><br/>
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.  [electronic resource] 

 -  American journal of hematology  Aug 2014 
 - 795-802 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-8652 
<br/><br/><label>Standard No.: </label>10.1002/ajh.23746  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Azacitidine--therapeutic use<br/>Drug Therapy, Combination<br/>Gene Expression<br/>Humans<br/>Immunologic Factors--therapeutic use<br/>Interferon-gamma--biosynthesis<br/>Interleukin-2--biosynthesis<br/>Lenalidomide<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Receptors, Tumor Necrosis Factor, Type II--antagonists & inhibitors<br/>Recurrence<br/>Remission Induction<br/>T-Lymphocytes, Cytotoxic--drug effects<br/>T-Lymphocytes, Regulatory--drug effects<br/>Thalidomide--analogs & derivatives